195 related articles for article (PubMed ID: 24304938)
1. Relationship between galectin-3 levels and mineralocorticoid receptor antagonist use in heart failure: analysis from HF-ACTION.
Fiuzat M; Schulte PJ; Felker M; Ahmad T; Neely M; Adams KF; Donahue MP; Kraus WE; Piña IL; Whellan DJ; O'Connor CM
J Card Fail; 2014 Jan; 20(1):38-44. PubMed ID: 24304938
[TBL] [Abstract][Full Text] [Related]
2. The prognostic value of plasma galectin-3 in chronic heart failure patients is maintained when treated with mineralocorticoid receptor antagonists.
Koukoui F; Desmoulin F; Galinier M; Barutaut M; Caubère C; Evaristi MF; Murat G; De Boer R; Berry M; Smih F; Rouet P
PLoS One; 2015; 10(3):e0119160. PubMed ID: 25786035
[TBL] [Abstract][Full Text] [Related]
3. Galectin-3 and mineralocorticoid receptor antagonist use in patients with chronic heart failure due to left ventricular systolic dysfunction.
Gandhi PU; Motiwala SR; Belcher AM; Gaggin HK; Weiner RB; Baggish AL; Fiuzat M; Brunner-La Rocca HP; Januzzi JL
Am Heart J; 2015 Mar; 169(3):404-411.e3. PubMed ID: 25728731
[TBL] [Abstract][Full Text] [Related]
4. Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure.
Lok DJ; Lok SI; Bruggink-André de la Porte PW; Badings E; Lipsic E; van Wijngaarden J; de Boer RA; van Veldhuisen DJ; van der Meer P
Clin Res Cardiol; 2013 Feb; 102(2):103-10. PubMed ID: 22886030
[TBL] [Abstract][Full Text] [Related]
5. Effect of Mineralocorticoid Receptor Antagonists on Cardiac Structure and Function in Patients With Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: A Meta-Analysis and Systematic Review.
Pandey A; Garg S; Matulevicius SA; Shah AM; Garg J; Drazner MH; Amin A; Berry JD; Marwick TH; Marso SP; de Lemos JA; Kumbhani DJ
J Am Heart Assoc; 2015 Oct; 4(10):e002137. PubMed ID: 26459931
[TBL] [Abstract][Full Text] [Related]
6. Association of mineralocorticoid receptor antagonist use and in-hospital outcomes in patients with acute heart failure.
Bistola V; Simitsis P; Farmakis D; Ikonomidis I; Bakosis G; Triposkiadis F; Hatziagelaki E; Lekakis J; Mebazaa A; Parissis J
Clin Res Cardiol; 2018 Jan; 107(1):76-86. PubMed ID: 28921054
[TBL] [Abstract][Full Text] [Related]
7. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial.
Lopez-Andrès N; Rossignol P; Iraqi W; Fay R; Nuée J; Ghio S; Cleland JG; Zannad F; Lacolley P
Eur J Heart Fail; 2012 Jan; 14(1):74-81. PubMed ID: 22089058
[TBL] [Abstract][Full Text] [Related]
8. Anemia and associated clinical outcomes in patients with heart failure due to reduced left ventricular systolic function.
McCullough PA; Barnard D; Clare R; Ellis SJ; Fleg JL; Fonarow GC; Franklin BA; Kilpatrick RD; Kitzman DW; O'Connor CM; Piña IL; Thadani U; Thohan V; Whellan DJ;
Clin Cardiol; 2013 Oct; 36(10):611-20. PubMed ID: 23929781
[TBL] [Abstract][Full Text] [Related]
9. Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee.
Butler J; Ezekowitz JA; Collins SP; Givertz MM; Teerlink JR; Walsh MN; Albert NM; Westlake Canary CA; Carson PE; Colvin-Adams M; Fang JC; Hernandez AF; Hershberger RE; Katz SD; Rogers JG; Spertus JA; Stevenson WG; Sweitzer NK; Tang WH; Stough WG; Starling RC
J Card Fail; 2012 Apr; 18(4):265-81. PubMed ID: 22464767
[TBL] [Abstract][Full Text] [Related]
10. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction.
Udelson JE; Feldman AM; Greenberg B; Pitt B; Mukherjee R; Solomon HA; Konstam MA
Circ Heart Fail; 2010 May; 3(3):347-53. PubMed ID: 20299607
[TBL] [Abstract][Full Text] [Related]
11. Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study.
Felker GM; Fiuzat M; Shaw LK; Clare R; Whellan DJ; Bettari L; Shirolkar SC; Donahue M; Kitzman DW; Zannad F; Piña IL; O'Connor CM
Circ Heart Fail; 2012 Jan; 5(1):72-8. PubMed ID: 22016505
[TBL] [Abstract][Full Text] [Related]
12. The Effectiveness of Eplerenone vs Spironolactone on Left Ventricular Systolic Function, Hospitalization and Cardiovascular Death in Patients With Chronic Heart Failure-HFrEF.
Naser N; Durak-Nalbantic A; Sabanovic-Bajramovic N; Karic A
Med Arch; 2023 Apr; 77(2):105-111. PubMed ID: 37260796
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF.
Jering KS; Zannad F; Claggett B; Mc Causland FR; Ferreira JP; Desai A; Barkoudah E; McMurray JJV; Pfeffer MA; Solomon SD
JACC Heart Fail; 2021 Jan; 9(1):13-24. PubMed ID: 33189633
[TBL] [Abstract][Full Text] [Related]
14. Association of Mineralocorticoid Receptor Antagonist Use With All-Cause Mortality and Hospital Readmission in Older Adults With Acute Decompensated Heart Failure.
Yaku H; Kato T; Morimoto T; Inuzuka Y; Tamaki Y; Ozasa N; Yamamoto E; Yoshikawa Y; Kitai T; Taniguchi R; Iguchi M; Kato M; Takahashi M; Jinnai T; Ikeda T; Nagao K; Kawai T; Komasa A; Nishikawa R; Kawase Y; Morinaga T; Toyofuku M; Seko Y; Furukawa Y; Nakagawa Y; Ando K; Kadota K; Shizuta S; Ono K; Sato Y; Kuwahara K; Kimura T;
JAMA Netw Open; 2019 Jun; 2(6):e195892. PubMed ID: 31225889
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of mineralocorticoid receptor antagonist in patients with heart failure with preserved ejection fraction.
Suzuki S; Motoki H; Kanzaki Y; Maruyama T; Hashizume N; Kozuka A; Yahikozawa K; Kuwahara K
ESC Heart Fail; 2020 Oct; 7(5):2752-2761. PubMed ID: 32592265
[TBL] [Abstract][Full Text] [Related]
16. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3.
Bayes-Genis A; de Antonio M; Vila J; Peñafiel J; Galán A; Barallat J; Zamora E; Urrutia A; Lupón J
J Am Coll Cardiol; 2014 Jan; 63(2):158-66. PubMed ID: 24076531
[TBL] [Abstract][Full Text] [Related]
17. Predictors of the Use of Mineralocorticoid Receptor Antagonists in Patients With Left Ventricular Dysfunction Post-ST-Segment-Elevation Myocardial Infarction.
Wong EC; Fordyce CB; Wong G; Lee T; Perry-Arnesen M; Mackay M; Singer J; Cairns JA; Turgeon RD
J Am Heart Assoc; 2021 Jul; 10(14):e019167. PubMed ID: 34227405
[TBL] [Abstract][Full Text] [Related]
18. Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial.
Desai AS; Vardeny O; Claggett B; McMurray JJ; Packer M; Swedberg K; Rouleau JL; Zile MR; Lefkowitz M; Shi V; Solomon SD
JAMA Cardiol; 2017 Jan; 2(1):79-85. PubMed ID: 27842179
[TBL] [Abstract][Full Text] [Related]
19. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
Martin N; Manoharan K; Davies C; Lumbers RT
Cochrane Database Syst Rev; 2021 May; 5(5):CD012721. PubMed ID: 34022072
[TBL] [Abstract][Full Text] [Related]
20. Prevalent digoxin use and subsequent risk of death or hospitalization in ambulatory heart failure patients with a reduced ejection fraction-Findings from the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) randomized controlled trial.
Ambrosy AP; Bhatt AS; Stebbins AL; Wruck LM; Fudim M; Greene SJ; Kraus WE; O'Connor CM; Piña IL; Whellan DJ; Mentz RJ
Am Heart J; 2018 May; 199():97-104. PubMed ID: 29754673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
